Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPTLC2 | O15270 | 7/20 | 0.83 |
| ▸ | SPTLC3 | Q9NUV7 | 3/20 | 0.83 |
| ▸ | PTK2 | Q05397 | 5/20 | 0.40 |
| ▸ | KDM5A | P29375 | 1/20 | 0.39 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.38 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19893152 | 1.00 | SPTLC2 (0.83) | SPTLC2SPTLC3PTK2KDM5AKCNK3 | |
| SCHEMBL19893231 | 1.00 | SPTLC2 (0.83) | SPTLC2SPTLC3PTK2KDM5AKCNK3 | |
| SCHEMBL19893654 | 0.91 | SPTLC2 (0.79) | SPTLC2SPTLC3PTK2KDM5AKCNK3 | |
| SCHEMBL19893533 | 0.91 | SPTLC2 (0.77) | SPTLC2SPTLC3KDM5AKCNK3KCNK9 | |
| SCHEMBL19893488 | 0.91 | SPTLC2 (0.80) | SPTLC2SPTLC3PTK2KDM5AKCNK3 | |
| SCHEMBL19892760 | 0.91 | SPTLC2 (1.00) | SPTLC2SPTLC3PTK2KDM5AKCNK3 | |
| SCHEMBL19893714 | 0.91 | SPTLC2 (0.80) | SPTLC2SPTLC3PTK2KDM5AKCNK3 | |
| SCHEMBL19893417 | 0.91 | SPTLC2 (0.80) | SPTLC2SPTLC3PTK2KDM5AKCNK3 | |
| SCHEMBL19893288 | 0.91 | SPTLC2 (1.00) | SPTLC2SPTLC3PTK2KDM5AKCNK3 | |
| SCHEMBL19893173 | 0.91 | SPTLC2 (1.00) | SPTLC2SPTLC3PTK2KDM5AKCNK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3287441-B1 | ACYLATED 4-AMINOPIPERIDINES AS INHIBITORS OF SERINE PALMITOYLTRANSFERASE | TAKEDA PHARMACEUTICALS CO (JP) | 2021-06-09 | — | — | EP | disclosed |
| US-10189785-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICALS COMPANY LIMITED (JP) | 2019-01-29 | — | — | US | disclosed |
| US-10189785-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICALS COMPANY LIMITED (JP) | 2019-01-29 | — | — | US | disclosed |
| US-20180170874-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-21 | — | — | US | disclosed |
| US-20180170874-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-21 | — | — | US | disclosed |
| US-20180170874-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-21 | — | — | US | disclosed |
| EP-3287441-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10189785-B2 | Heterocyclic compound | SPTLC1, SPTLC2, NPC1 | SPTLC2 2/4885SPTLC3 4/4885PTK2 4690/4885 |
| US-20180170874-A1 | HETEROCYCLIC COMPOUND | SPTLC1, SPTLC2, NPC1 | SPTLC2 2/4885SPTLC3 4/4885PTK2 4690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.